TaleNeprilysin and Neprilysin inhibition in chronic kidney disease

Autor: Richard Haynes, Parminder K. Judge
Rok vydání: 2021
Předmět:
medicine.medical_specialty
medicine.drug_class
medicine.medical_treatment
Population
030232 urology & nephrology
Renal function
Angiotensin-Converting Enzyme Inhibitors
030204 cardiovascular system & hematology
urologic and male genital diseases
Sacubitril
Renin-Angiotensin System
Angiotensin Receptor Antagonists
Mice
03 medical and health sciences
0302 clinical medicine
Glucosides
Internal medicine
Internal Medicine
Natriuretic peptide
Animals
Humans
Medicine
Renal replacement therapy
Benzhydryl Compounds
Renal Insufficiency
Chronic
Natriuretic Peptides
education
Sodium-Glucose Transporter 2 Inhibitors
Heart Failure
education.field_of_study
business.industry
Aminobutyrates
Biphenyl Compounds
medicine.disease
Disease Models
Animal
Drug Combinations
Valsartan
Cardiovascular Diseases
Nephrology
Heart failure
Chronic Disease
Disease Progression
Cardiology
Neprilysin
business
Kidney disease
medicine.drug
Zdroj: Current Opinion in Nephrology & Hypertension. 30:123-130
ISSN: 1473-6543
1062-4821
DOI: 10.1097/mnh.0000000000000659
Popis: Purpose of review Chronic kidney disease (CKD) is associated with increased risk of progression to end-stage kidney disease and cardiovascular events. There is limited evidence that available treatments have beneficial effects on cardiorenal outcomes in all people with nondiabetic CKD. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD. Recent findings NEPi enhances the activity of the natriuretic peptide system producing natriuresis, diuresis and inhibition of the renin–angiotensin system and sympathetic nervous system. Sacubitril/valsartan is the first Angiotensin receptor-neprilysin inhibitor (ARNI) to be produced and has been shown to substantially improve cardiovascular outcomes in heart failure and delay progression of kidney disease in this population. Although ARNIs have not shown similar effects on kidney function in the short-to-medium term in people with CKD, they are associated with substantial reductions in cardiac biomarkers and blood pressure in CKD. Summary These data suggest that NEPi with an ARNI could benefit patients with CKD by reducing the risk of cardiovascular disease and have the possibility of retarding the progression of CKD (hence delaying the need for renal replacement therapy).
Databáze: OpenAIRE
Externí odkaz: